Drugs / B. infantis
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02286999 | Oct 2015 → Jan 2018 | atopic eczema, food allergy | Emanual Maverakis, MD | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT06102213 | Sep 2023 → Aug 2024 | hematopoietic and lymphoid cell neoplasm | Prolacta Bioscience | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B. infantis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02286999 ↗ |
| Known as | Bifidobacterium longum subsp. infantis | “Herein we propose a novel phase I ascending dose trial of Bifidobacterium longum subsp. infantis (B. infantis) to identify the dose required to produce predominant gut...” PMID 27449926 ↗ Jul 2016 |
| Modality | Other / unclassified | “two doses of the probiotic Bifidobacterium longum subsp. infantis (B. infantis)” NCT02286999 ↗ |
| Route | Oral | “B. infantis will be administered orally twice a day (BID)” NCT06102213 ↗ |